LAMEA Large Molecule Bioanalytical Testing Services Market Size, 2028

LAMEA Large Molecule Bioanalytical Testing Services Market Size, Share & Industry Trends Analysis Report By End-user (SMEs and Large Firms), By Test Type, By Type (ADA, Pharmacokinetics), By Phase, By Therapeutic Areas, By Country and Growth Forecast, 2022 - 2028

Published Date: November-2022 | Number of Pages: 122 | Format: PDF | Report ID: KBV-20913

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


COVID-19

Get in-depth analysis of the COVID-19 impact on the LAMEA Large Molecule Bioanalytical Testing Services Market

Market Report Description

The Latin America, Middle East and Africa Large Molecule Bioanalytical Testing Services Market would witness market growth of 12.5% CAGR during the forecast period (2022-2028).

Due to its target specificity, decreased toxicity, and increased potency, large-molecule therapies have become more popular recently. As a result, numerous pharmaceutical companies now provide a wide range of large-molecule medications. The usage of LC-MS has increased along with the utilization of large-molecule medicines. Although LBAs remain the industry standard for large-molecule quantification, LC-MS provides various advantages, including multiplexing and a wider linear dynamic range. The use of LC-MS for these chemicals still faces a number of difficulties, though.

The market for large molecule bioanalytical testing services is anticipated to rise as a result of the increasing complexity of product engineering & designs and the rising need for sophisticated and top-notch testing services. Pharmaceutical companies are under increased pressure to adopt new technologies into their services to meet consumer demand as a result of the swift improvements in healthcare. Due to faster time to market, increased regulatory scrutiny, and a higher risk of product failure, there is an increasing demand for large molecule bioanalytical testing services.

In recent years, Abu Dhabi and Dubai have both made efforts to promote medical innovation and ensure that their citizens have access to medical treatment of the highest possible standard. The Health Authority in Abu Dhabi is working to improve the quality of care, expand access to services, transition from public to private providers in a safe and efficient manner, and implement a latest financing model through an innovative system of mandatory health insurance. The rising investment in the healthcare sector of UAE would support the market growth in the region.

The Brazil market dominated the LAMEA Large Molecule Bioanalytical Testing Services Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $45.4 million by 2028. The Argentina market is showcasing a CAGR of 13.1% during (2022 - 2028). Additionally, The UAE market would register a CAGR of 12.2% during (2022 - 2028).

Based on End-user, the market is segmented into SMEs and Large Firms. Based on Test Type, the market is segmented into Bioavailability, ADME, PD, Bioequivalence, and Others. Based on Type, the market is segmented into ADA, Pharmacokinetics, and Others. Based on Phase, the market is segmented into Clinical and Pre-clinical (With Antibody and Without Antibody (ELISA Based Assay)). Based on Therapeutic Areas, the market is segmented into Oncology, Neurology, Infectious Diseases, Cardiology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: The Global Large Molecule Bioanalytical Testing Services Market is Predict to reach $2.8 Billion by 2028, at a CAGR of 9.1%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Laboratory Corporation Of America Holdings, IQVIA Holdings, Inc., Syneos Health, Inc., SGS S.A., Intertek Group PLC, Pace Analytical Services, LLC, ICON Plc, Charles River Laboratories International, Inc., and Thermo Fisher Scientific, Inc.

Scope of the Study

Market Segments Covered in the Report:

By End-user

  • SMEs
  • Large Firms

By Test Type

  • Bioavailability
  • ADME
  • PD
  • Bioequivalence
  • Others

By Type

  • ADA
  • Pharmacokinetics
  • Others

By Phase

  • Clinical
  • Pre-clinical
    • With Antibody
    • Without Antibody (ELISA Based Assay)

By Therapeutic Areas

  • Oncology
  • Neurology
  • Infectious Diseases
  • Cardiology
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Laboratory Corporation Of America Holdings
  • IQVIA Holdings, Inc.
  • Syneos Health, Inc.
  • SGS S.A.
  • Intertek Group PLC
  • Pace Analytical Services, LLC
  • ICON Plc
  • Charles River Laboratories International, Inc.
  • Thermo Fisher Scientific, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

Global Large Molecule Bioanalytical Testing Services Market Report 2022-2028

North America Large Molecule Bioanalytical Testing Services Market Report 2022-2028

Europe Large Molecule Bioanalytical Testing Services Market Report 2022-2028

Asia Pacific Large Molecule Bioanalytical Testing Services Market Report 2022-2028

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities